72 unknown, 66 recruiting, 45 completed, 35 not yet recruiting. 280 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 280 | Unknown 72, Recruiting 66, Completed 45, Not yet recruiting 35, Terminated 30, Active not recruiting 14, Withdrawn 12, Suspended 6 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia SNC116 - B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Shanghai Simnova Biotechnology Co.,Ltd. | 28 | 2026-09-01 | 2026-09-21 |
| A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement Anselamimab - AL Amyloidosis | Early Phase 1 | Not yet recruiting | Stanford University | 5 | 2026-09-01 | 2026-10-27 |
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) Iberdomide, CAR-T Leukapheresis, CAR-T Infusion - Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Not yet recruiting | Shambavi Richard | 22 | 2026-07-01 | 2026-07-27 |
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma RN9101 injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 19 | 2026-07-01 | 2026-06-10 |
| GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma GoFast CD19 CAR T Cells - Relapsed or Refractory Large B-cell Lymphoma | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 9 | 2026-06-30 | 2026-06-26 |
| Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Chimeric Antigen Receptor T Cells (CAR-T) - Relapsed/Refractory Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Chulalongkorn University | 3 | 2026-06-01 | 2026-03-09 |
| CAR-T Cell Therapy for ALL CAR-T cell infusion - Relapsed Acute Lymphoblastic Leukemia (ALL) | Early Phase 1 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-10 |
| A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy humanized CD19 CAR-T Cells with TLR2 - B Lymphoblastic Leukemia/Lymphoma | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 60 | 2026-06-01 | 2026-01-12 |
| A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) - ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome) | Early Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 24 | 2026-05-14 | 2026-06-11 |
| RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas RN1701 injection - Relapsed/Refractory B-cell Lymphoma | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 10 | 2026-05-08 | 2026-05-04 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine EBV mRNA vaccine - HIV Associated Lymphoma | Early Phase 1 | Not yet recruiting | West China Hospital | 6 | 2026-05-01 | 2026-05-01 |
| Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma CD19/CD20 Tandem Dual CAR-T - Relapsed/Refractory B-Cell Lymphoma | Early Phase 1 | Not yet recruiting | Affiliated Hospital to Academy of Military Medical Sciences | 20 | 2026-04-30 | 2026-04-29 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
| Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma GI001 Injection - B-Cell Non-Hodgkin Lymphoma | Early Phase 1 | Not yet recruiting | Ruijin Hospital | 9 | 2026-04-20 | 2026-05-13 |
| A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. QI-019B Injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-04-15 | 2026-04-20 |
| A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma IMV102 treatment - Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-04-14 | 2026-09-03 |
| CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation CAR19BCMA-T cells, fludarabine and cyclophosphamide - Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation | Early Phase 1 | Not yet recruiting | Affiliated Hospital to Academy of Military Medical Sciences | 20 | 2026-04-02 | 2026-04-08 |
Showing 20 of 280. Sign in to see all of them.
Multiple Myeloma (87) · Lymphoma (41) · Lymphoma, B-Cell (37) · Lymphoma, Non-Hodgkin (37) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Burkitt Lymphoma (29) · Recurrence (25) · Lymphoma, Large B-Cell, Diffuse (21) · Lymphoma, Follicular (19) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, Mantle-Cell (15) · Leukemia (13) · Hodgkin Disease (12) · Leukemia, Myeloid, Acute (12) · Lymphoma, T-Cell (9)
Immune System Diseases (280) · Hemic and Lymphatic Diseases (277) · Immunoproliferative Disorders (275) · Neoplasms by Histologic Type (274) · Neoplasms (269) · Lymphatic Diseases (200) · Hematologic Diseases (156) · Lymphoma (125) · Lymphoma, Non-Hodgkin (96) · Paraproteinemias (94) · Blood Protein Disorders (92) · Neoplasms, Plasma Cell (92) · Cardiovascular Diseases (91) · Vascular Diseases (91)
Cyclophosphamide (25) · fludarabine (14) · Dexamethasone (11) · Rituximab (10) · Granulocyte Colony-Stimulating Factor (7) · Bortezomib (6) · Etoposide (6) · Filgrastim (6) · Immunotherapy, Adoptive (6) · Vincristine (6) · Doxorubicin (5) · Lenalidomide (5) · Melphalan (5) · 68Ga-pentixafor (4) · Fluorodeoxyglucose F18 (4)
Zhejiang University (17) · Institute of Hematology & Blood Diseases Hospital, China (12) · Washington University School of Medicine (9) · Memorial Sloan Kettering Cancer Center (6) · Shanghai Changzheng Hospital (6) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) · Allife Medical Science and Technology Co., Ltd. (5) · Anhui Provincial Hospital (5) · He Huang (5) · Hebei Yanda Ludaopei Hospital (5) · Hrain Biotechnology Co., Ltd. (5) · M.D. Anderson Cancer Center (5) · Mayo Clinic (5) · Northwestern University (5) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (5)
China (136) · United States (102) · Australia (2) · Denmark (2) · Sweden (2) · Canada (1) · Czechia (1) · France (1) · Indonesia (1) · Italy (1) · Pakistan (1) · Spain (1) · Thailand (1)
Fang Liu, MD, PhD (3) · Farrokh Dehdashti, M.D. (3) · He Huang, MD (3) · Hongyu Zhang, MD, PhD (3) · Jianmin Luo, PhD&MD (3) · Ariela Noy, MD (2) · Hai Yi, M.D. & Ph.D. (2) · Jeffrey J. Raizer, MD (2) · Jinxing Lou (2) · John F DiPersio, M.D., Ph.D. (2) · Juan Du, Doctor (2) · Lubomir Sokol, MD, PhD (2) · Peihua Lu, PhD&MD (2) · Pengcheng He, M.D. Ph.D. (2) · Qing Zhang, Doctoral (2)
PMID 37192741, PMID 39501801, PMID 40540129, PMID 18042692, PMID 19880495, PMID 20671118, PMID 23023715, PMID 23649469, PMID 24142051, PMID 26202875, PMID 26222726, PMID 26353084, PMID 26424652, PMID 27269947, PMID 28911074, PMID 29272362, PMID 29652233, PMID 29920566, PMID 29925499, PMID 30846271, PMID 31776631, PMID 32298202, PMID 32826320, PMID 32840736, PMID 32989091, PMID 33242451, PMID 33626253, PMID 33851477, PMID 34344873, PMID 34435552, PMID 34651291, PMID 34677626, PMID 35177672, PMID 35349631, PMID 35468680, PMID 35973200, PMID 36189306, PMID 36719647, PMID 36725117, PMID 36762851, PMID 36808074, PMID 36923556, PMID 37077913, PMID 37093350, PMID 37272512, PMID 37735756, PMID 37781191, PMID 38143760, PMID 38230766, PMID 38592213
P30CA033572 (3), P30CA006973 (2), P30CA043703 (2), P30CA072720 (2), 2019 (1), K12CA090433 (1), P01CA015396 (1), P01CA068484 (1), P30CA006516 (1), P30CA012197 (1), P30CA015083 (1), P30CA036727 (1), P30CA060553 (1), P30CA138292 (1), P50CA097274 (1)